The quadrivalent human papillomavirus vaccine: erythema multiforme and cutaneous side effects after administration.

The quadrivalent human papillomavirus (qHPV) vaccine, the first vaccine for use in the prevention of cervical cancer and condyloma acuminatum, was approved in June 2006. In 2008, the mass media reported suspected links between the qHPV vaccine and serious adverse events; however, several studies have found that the vaccine is safe and the main adverse events are mild local reactions. Erythema multiforme (EM) is an acute self-limited cutaneous or mucocutaneous syndrome characterized by the abrupt onset of symmetric target lesions. The clinical manifestations and histological features of EM, Stevens-Johnson syndrome and toxic epidermal necrolysis show considerable overlap, and they are classically considered to represent a spectrum of skin disorders. We present a case of EM following qHPV vaccination to review the cutaneous side effects of this vaccine and the possibility of more serious side effects with the administration of booster doses.

Successful treatment of large venous malformation with dual wavelength 595 and 1064 nm system.

Venous malformations (VMs) are congenital soft, compressible, non-pulsatile blue-purple masses. VMs present a therapeutic challenge. They can be treated with surgery or sclerotherapy as well as with several lasers. We report the successful treatment of two patients with large VMs with combined sequential application of 595 nm pulsed dye laser and 1064 nm Nd:YAG wavelengths. At the end of the treatment course, total volume reduction was observed in both. All sessions were well tolerated without anesthesia. In our patients, using this sequential laser device achieved an almost complete clearance of the VM with no scarring.